Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ... [Yahoo! Finance]
Relmada Therapeutics, Inc. (RLMD)
NASDAQ:AMEX Investor Relations:
ir.relmada.com
Company Research
Source: Yahoo! Finance
Cash Used in Operations: $16.7 million for the third quarter ended September 30, 2024, compared to $11.6 million for the same period in 2023. Research and Development Expense: $11.1 million for Q3 2024, up from $10.5 million in Q3 2023. General and Administrative Expense: $11.9 million for Q3 2024, down from $12.2 million in Q3 2023. Net Loss: $21.7 million or 72 per share for Q3 2024, compared to $22 million or 73 per share in Q3 2023. Common Shares Outstanding: 30.2 million as of November 4, 2024. Warning! GuruFocus has detected 2 Warning Signs with RLMD. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Relmada Therapeutics Inc ( NASDAQ:RLMD ) is advancing the development of new treatments for CNS disorders, including major depressive disorder (MDD), with a focus on derisking study design and execution. The company expects to report the outcome of the interim analysis for the Relian
Show less
Read more
Impact Snapshot
Event Time:
RLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLMD alerts
High impacting Relmada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLMD
News
- Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017GlobeNewswire
- Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.MarketBeat
- Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at Mizuho from a "strong-buy" rating to a "hold" rating.MarketBeat
- Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $1.00 price target on the stock, down previously from $10.00.MarketBeat
- Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $1.00 price target on the stock, down previously from $23.00.MarketBeat
RLMD
Earnings
- 11/7/24 - Miss
RLMD
Sec Filings
- 12/9/24 - Form 8-K
- 11/14/24 - Form SC
- 11/7/24 - Form 10-Q
- RLMD's page on the SEC website